Journal of Nephropharmacology (Jan 2021)

Glucoherb versus metformin on glycemic markers and glycosylated hemoglobin in prediabetes patients; a clinical trial study

  • Iman Izadi,
  • Rahil Riahi Samani,
  • Afsaneh Malekpour Tehrani,
  • Marziyeh Dehghani,
  • Alireza Jafari

DOI
https://doi.org/10.34172/npj.2021.08
Journal volume & issue
Vol. 10, no. 1
pp. e08 – e08

Abstract

Read online

Introduction: There is a high risk of diabetes mellitus in pre-diabetic patients. Objectives: The aim of the study was to compare the effect of the extracts of these herbs in the formulation of Glucoherb supplementation versus metformin in pre-diabetes patients on glycemic markers and glycosylated hemoglobin. Patients and Methods: Pre-diabetic patients who had indication of drug treatment according to the criteria of the American Diabetes Association, were selected and randomly divided into two groups of Glucoherb and metformin. Body mass index (BMI), fasting blood sugar (FBS), 2 hours postprandial blood glucose (BS2PP) and glycosylated hemoglobin (HbA1c) were measured before and after the intervention. Results: The mean BMI, FBS, BS2PP and HbA1c levels were significantly decreased after intervention in both Glucoherb and metformin groups (P < 0.05) without any significant difference between them (P < 0.05). Conclusion: Glucoherb showed similar efficacy to metformin in reducing blood glucose, BMI and HbA1c in pre-diabetic patients.

Keywords